Study On The Applied Timing Of Ginkgo Biloba Extract In Cerebral Hemorrhage Of Hypertensive Unilateral Basal Ganglia

Objective:The patients were selected for multiple analysis and comparison to explore the application of ginkgo biloba extract(EGb761)in the treatment of hypertensive intracerebral hemorrhage and assessed its security,while providing theoretical support for EGb761 in the application of cerebral hemorrhage in clinical work.Methods:The 90 patients with hypertensive intracerebral hemorrhage were divided into experimental group 1,experimental group 2 and control group,each group of 30 cases,who met the inclusion criteria and who were hospitalized in Department of Neurology,Shanxi Provincial People's Hospital from February 2016 to March 2017.At the time of admission,all patients were recorded for general information,including age,systolic blood pressure,diastolic blood pressure,body temperature,immediate blood glucose,admission delay time,head CT hematoma volume,NIHSS score and other data.Three groups of patients,with reference to China Cerebral Vascular Disease 2014 guidelines issued by the Chinese Medical Association,were developed for treatment.One week after hospitalization,experimental group 1 was treated with EGb761 injection,70mg intravenous infusion of 1 times / day,Treatment for 14 days and experimental group 2 with EGb761 injection two weeks after hospitalization,70 mg intravenous infusion of 1 times / day,Treatment for 14 days too.At the same time the datafrom the head CT hematoma volume,NIHSS score were subtracted by the brain CT hematoma volume and NIHSS score at admission and were recorded.The data were processed by spss17.0 statistical software,and The variance analysis was applied for speculating whether there was a difference between the three groups,and SNK-q test was used to complete a comprehensive three sets of data,while P <0.05 was considered statistically significant.Results:After statistical analysis the age at admission,systolic and diastolic blood pressure,immediate blood glucose,body temperature,and admission delay time were not statistically significant and can be compared(P>0.05).After normality test and variance homogeneity test,the difference of intracranial hematoma volume and NIHSS score was consistent with normal distribution and variance homogeneity.the difference of intracranial hematoma volume and NIHSS score was considered statistically different(P<0.05).After appling SNK-q test to complete a comprehensive comparison,statistical differences of three sets of data were found:the difference of the head hematoma volume and the NIHSS score in the experimental group 2 was greater than that in the control group,while the difference in the experimental group1 was significantly higher than that of the experimental group 2 and the control group(P<0.05).Conclusion:In the absence of contraindications case,patients with hypertensive intracerebral hemorrhage can be treated with EGB761 for one week,at the same time,hematoma absorption time was significantly shortened and neurological deficits were Obviously improved.In the early stage of hypertensive intracerebral hemorrhage,the probability ofintracranial rebleeding and other adverse reactions has not been increased after treatment with Ginkgo biloba extract.